Biofield Energy Therapy: Role in Multiple Organ Health Specific Biomarkers in Cell-Based Assay

Authors: Sakina Aleemah Ansari, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar and Snehasis Jana*

DOI: 10.23880/aabsc-16000136

Volume 2, Issue 2

Abstract

The major cause of high rate of mortality is the multiple organ dysfunction among critical care healthcare services. The aim of the current study was to evaluate the impact of the Biofield Energy Treated test formulation using standard and specific cell lines related with vital organs functioning. The test formulation and the specific cell media was divided into two parts; one part was untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Sakina Aleemah Ansari, USA and labeled as the Biofield Energy Treated (BT) test formulation/media. The test formulation was tested against various activities using cell line assay in their specific medium (Med). The test formulation was tested for cell viability, and the results showed that the test formulation at tested concentrations was found safe and non-toxic. Cytoprotective activity showed improved cellular restoration by 105.4% (at 25 μg/mL), 32.8% (at 25 μg/mL), and 151.8% (at 10 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BTMed + BT-TI groups respectively, as compared to the untreated test group in the human cardiac fibroblasts cells (HCF) cells, while improved restoration of cell viability by 22.4% (at 25.5 μg/mL), 67.1% (at 10 μg/mL), and 72.9% (at 10 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group in HepG2 cells. Cellular restoration in A549 cells was improved by 9.3%, 70.4%, and 14.1% at 0.1, 1, and 25.5 μg/mL respectively, in the BT-Med + UT-TI group, while 3% and 4.6% improved cellular restoration was reported at 10 and 25.5 μg/mL respectively, at BT-Med + BT-TI groups as compared to the untreated test group. ALP activity in Ishikawa cells was significantly increased by 68.4%, 41.1%, and 18.8% at 0.1, 10, and 50 μg/mL respectively, in the UT-Med + BTTI group, while in MG-63 cells showed maximum increased ALP activity by 92.7%, 84.5%, and 93.2% respectively in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI group respectively, at 50 μg/mL as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 51.6%, 88.7%, and 53.7% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, at 10 μg/mL as compared to the untreated group. Alanine amino transferase (ALT) activity was reported in terms of percent cellular protection of HepG2 (liver) cells. The test data showed improved HepG2 cells protection (represents decreased ALT activity) by 33%, 90.2%, and 72.1% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, at 25 μg/mL as compared to the untreated test group. Percentage cellular protection of A549 (lungs) cells (represents increased of SOD activity) was increased by 21.5% at 25.5 μg/mL in the UT-Med + BT-TI, while 33.4%, 25.8%, and 21.5% at 1, 10, and 25.5 μg/mL respectively, in the BT-Med + UT-TI group, and 12.8% increased SOD activity at 25.5 μg/mL in the BT-Med + BT-TI groups as compared to the untreated group. Serotonin level was significantly increased 137.4% (at 0.1 μg/mL), 65.4% (at 0.1 μg/mL), and 77.3% (at 10 μg/mL) in the UT-Med + BT-TI, BT-Med + UTTI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 24.2% (at 1 μg/mL), 213.7% (at 10 μg/mL), and 328.7% (at 10 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, the data concluded that The Trivedi Effect® would be significantly useful for improving multiple organs health, which can be used for many coronary artery diseases, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.

Keywords: The Trivedi Effect®; Biofield Energy Treatment; Organ health; Multiple organ failure; Bone health

View PDF